MAGNETIC RESONANCE IMAGING AGENTS FOR IN VIVO LABELING AND DETECTION OF AMYLOID DEPOSITS

摘要

In accordance with the objects outlined above, the present invention provides MRI agent compositions comprising a chelator, comprising a paramagnetic metal ion and an amyloid binding moiety (ABM). The chelator may be directly attached to the ABM or indirectly attached via a linker. The linker may be attached to either an internal or terminal position of the ABM. In an additional aspect, the invention provides ABMs that are selected from the group consisting of congo red, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy))-styrylbenzene (BSB), and chyrsamine G. These ABMs can be conjugated to chelators such as DOTA, DTPA and DOTEP comprising Gd(III). In an additional aspect, the invention provides MRI agents comprising chelators linked together using ABMs or polymers. In a further aspect, the provided pharmaceutical composition comprises an MRI agent of the invention and a pharmaceutically acceptable carrier. In an additional aspect, the present invention provides methods of magnetic resonance imaging of a cell, tissue or patient comprising administering an MRI agent of the invention to a cell, tissue or patient and rendering a magnetic resonance image of the cell, tissue or patient.